Combination Treatment Fails to Improve Survival in Recurrent Glioma Combination Treatment Fails to Improve Survival in Recurrent Glioma

Following tumor resection in patients with recurrent glioblastoma and anaplastic astrocytoma, treatment with vocimagene amiretrorepvec and with flucytosine provides no improvement in overall survival, according to an open-label phase 2/3 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news